CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced a strategic commercialization partnership with SteinCares, a leading pharmaceutical company with over 40 years of experience and a strong presence in Latin America.
Read Also – ADB, Ayala Sign $100 Mn Financing Deal to Support Electric Mobility in Philippines
Under this agreement, SteinCares will gain the commercialization rights for sugemalimab in 10 LATAM countries, including Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala and Ecuador.
Read Also – UmrahCash joins forces with Ashraqat
As part of this collaboration, SteinCares will be responsible for the regulatory affairs and commercialization activities of sugemalimab in these regions. CStone will supply sugemalimab and will receive upfront, regulatory, and commercial milestone payments as well as revenue from product supply.
Dr. Jason Yang, CEO, President of R&D and Executive Director at CStone, stated, “Following our successful market entries in Central and Eastern Europe, Switzerland, as well as the Middle East and Africa, we are excited to announce another key milestone in the global expansion of sugemalimab. As the first anti-PD-L1 monoclonal antibody approved in both the EU and UK for first-line, all-comer, Stage IV non-small cell lung cancer (NSCLC), sugemalimab is well-positioned for success in Latin America. SteinCares’ extensive distribution network and deep marketing expertise will significantly enhance sugemalimab’s reach.”
Mitchell Waserstein, CEO of SteinCares, added: “This agreement with CStone represents a significant step forward in our mission to create healthcare opportunities for patients in LATAM. At SteinCares, we are committed to providing more Latin Americans with greater access to safe, innovative, and affordable therapies. With our extensive experience and established sales network across the region, we are confident in our ability to successfully commercialize sugemalimab in LATAM and make a meaningful impact on patients’ health and well-being.”
About CStone
CStone, established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception.
About SteinCares
SteinCares is a leader in commercializing and distributing specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars, plasma-derived therapies and complex generics. With more than 40 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global pharmaceutical companies and the region’s healthcare providers.
